publication date: May. 17, 2019

Texas Senate approves $3 billion measure to renew CPRIT funding

By Claire Dietz

The Texas Senate May 10 passed a measure that would provide new funding for the Cancer Prevention and Research Institute of Texas.

The legislation, which authorizes a second installment of $3 billion in General Obligation Bonds for the institute, will now go on the ballot for Texas voters.

The Texas House of Representatives passed the measure, HJR 12, last month (The Cancer Letter, April 26). With the bill receiving Senate approval, a constitutional amendment to grant funds for CPRIT will be put to the ballot Nov. 5.

CPRIT was founded in 2007, when Texas voters authorized $3 billion in bonds to fund research and prevention programs throughout the state. Since its formation, CPRIT has awarded more than $2.26 billion in grants to Texas researchers, institutions, non-profit organizations and businesses (The Cancer Letter, March 22).

It is “gratifying and exciting” to see lawmakers in both chambers of the Texas legislature vote to approve HJR 12, said Kent Osborne, director of the Dan L Duncan Comprehensive Cancer Center at the Baylor College of Medicine.

“The program, after a few bumps in the road, has been very successful in all three mission areas of cancer research, product development, and prevention services, and CPRIT has also benefited the state economically,” Osborne said to The Cancer Letter.

“CPRIT has played a key role in furthering our mission to end cancer, and we are grateful to the legislature for getting us one step closer to 10 more years of funding opportunities,” Peter WT Pisters, president of MD Anderson, said in a statement. “This important source … Continue reading Texas Senate approves $3 billion measure to renew CPRIT funding

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.